Quick Facts

• Target Condition: Chronic Obstructive Pulmonary Disease (COPD)
• Main Goal: Provides relief from bronchospasm (airway narrowing).
• Use Context: Indicated for patients who are already on a regular aerosol bronchodilator but continue to experience evidence of bronchospasm and require a second bronchodilator.

---

Combivent Respimat is a prescribed therapy for managing Chronic Obstructive Pulmonary Disease (COPD), which includes conditions such as chronic bronchitis and emphysema. The treatment is specifically formulated to address bronchospasm, or the tightening of muscles around the airways, which is a key factor contributing to breathing difficulty in COPD.

Its main purpose is to support maintenance therapy for those who require more than one type of bronchodilator to maintain optimal airflow. By combining two distinct bronchodilating agents, the medication is designed to assist in opening the air passages in the lungs. This mechanism may help improve breathing ability and reduce certain symptoms associated with the condition. The combination is indicated for use in adults diagnosed with COPD who continue to exhibit signs of airway obstruction.

For a comprehensive overview of the approved clinical usage, indications, and safety information, consult the official prescribing information.

Combivent Respimat is indicated for the maintenance treatment of COPD in adults who require more than one bronchodilator. The official regulatory label defines specific patient groups who can or cannot use the medication.

Contraindications

The medication is contraindicated in patients with a history of hypersensitivity to any component of the drug product, or to atropine or its derivatives.

Age-Related Eligibility

Age Group	Regulatory Status
Pediatric (Under 18)	Not indicated; safety and efficacy have not been established.
Adults (18+ years)	Indicated population for COPD maintenance.
Geriatric	Permitted at the recommended dose; no specific limitations demonstrated.

Condition-Based Restrictions

Caution is advised when the medication is used by patients with: narrow-angle glaucoma; cardiovascular disorders (including coronary insufficiency, cardiac arrhythmias, and hypertension); prostatic hyperplasia or bladder-neck obstruction; convulsive disorders; hyperthyroidism; or diabetes mellitus.

Special Populations

• Hepatic/Renal Impairment: Pharmacokinetics have not been studied in patients with liver or kidney insufficiency, limiting established use in these groups.
• Pregnancy: Use is generally conditional; authorized only if the potential benefit justifies the potential risk, as stated in the labeling.

Interactions with other medicines and products

Official regulatory information for Combivent Respimat identifies several pharmacodynamic interaction patterns with other medicinal products. These interactions are categorized based on their official description in government labeling, which primarily mandates restrictions on co-administration.

---

Documented Interaction Classes

Category	Interacting Agents (Classes)	Regulatory Outcome/Restriction
Additive Effects	Other Anticholinergic Agents	Avoid Co-administration (Increased risk of adverse anticholinergic effects).
	Other Beta-adrenergic Agents	Avoid Co-administration (Increased risk of adverse cardiovascular effects).
Antagonistic Effect	Beta-receptor Blocking Agents	Inhibit the effect of albuterol (Antagonistic bronchodilating effect).
Potentiation Risk	Non-Potassium Sparing Diuretics	May acutely worsen hypokalemia and ECG changes associated with beta-agonists.
	Monoamine Oxidase Inhibitors (MAOIs) or Tricyclic Antidepressants (TCAs)	Extreme Caution or use avoided within two weeks of discontinuation (Potentiation of cardiovascular effects).

---

The interaction profile is strongly structured around the pharmacologic classes of its two active ingredients, ipratropium bromide and albuterol sulfate. Combining the medication with other agents from these respective classes, such as other anticholinergics or beta-agonists, is officially advised against due to the high risk of additive systemic effects. Furthermore, the label requires specific precautions when used alongside MAOIs, TCAs, and certain diuretics, primarily due to the potential for severe cardiovascular or electrolyte potentiation.

The mechanism of Combivent Respimat is founded on the complementary physiological effect achieved by modulating two independent neural pathways that regulate the diameter of the airways.

One component, ipratropium, acts as a non-selective antagonist (blocker) on muscarinic receptors ( M1, M2, and M3) in the airways. This action targets the parasympathetic autonomic pathway, inhibiting the constricting signal mediated by the neurotransmitter acetylcholine. By blocking these receptors, ipratropium modulates the primary neural signal for smooth muscle contraction, which reduces bronchial smooth muscle tone.

The second component, albuterol, works as a selective agonist (activator) of Beta-2 (boldsymbolbetamathbf2)-adrenergic receptors on airway smooth muscle cells. This interaction triggers an intracellular cascade, increasing the level of cyclic adenosine monophosphate ( cAMP). This molecular change results in the active relaxation of the smooth muscle tissue, supporting the increase of the airway lumen diameter. This dual-action approach results in a combined physiological adjustment of airway tone.

Combivent Respimat is administered exclusively via oral inhalation as a fixed-dose maintenance treatment for chronic obstructive pulmonary disease (COPD). The medication is intended to be used on a regular, scheduled basis, not for immediate, acute breathing problems.

Standard Administration and Frequency

The standard adult regimen involves administering one inhalation (puff) four times a day (q.i.d.). This combination therapy is indicated only for use in adults; safety and efficacy have not been established for pediatric patients.

The total daily use is restricted by a strict maximum limit. Patients must not exceed six inhalations in any 24-hour period, even if additional puffs are taken for symptom relief outside the scheduled administration times. If a scheduled dose is missed, patients should take only the next dose at the regularly scheduled time and must not take a double dose to compensate for the omission.

Preparation and Device Management

Proper use requires specific steps related to the Respimat delivery system. The inhaler must be primed with four test sprays before its initial use and reprimed if left unused for specified durations. The device is designed to deliver 120 metered actuations, equating to approximately 30 days of medication. The entire unit must be discarded three months after the cartridge is first inserted, regardless of the remaining liquid.

Overview of Efficacy Trials

Combivent Respimat (ipratropium bromide and albuterol sulfate) is an inhaled combination medication studied for the maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD). The key clinical trials focused on establishing its bronchodilator effectiveness and safety profile, primarily in comparison to its individual components and the predecessor product, Combivent MDI.

---

Key Clinical Trial Findings

Clinical studies in patients with COPD demonstrated that the combination of ipratropium and albuterol resulted in statistically significant greater improvement in lung function than either component administered alone. This was measured primarily by Forced Expiratory Volume in 1 second (FEV1), a standard measure of breathing capacity.

• Superiority to Components: The combination product was shown to be superior to ipratropium monotherapy (ipratropium only) over the first four hours of the dosing interval, which confirmed the therapeutic contribution of the albuterol component.
• Comparability to Predecessor: A 12-week randomized, double-blind, placebo, and active-controlled trial established that Combivent Respimat was clinically comparable to the older Combivent MDI in terms of FEV1 response over six hours. This finding was a key factor in its regulatory approval as a propellant-free alternative.

---

The Respimat Device and Delivery

Studies comparing the Respimat Soft Mist Inhaler to traditional Metered-Dose Inhalers (MDIs) showed that the Respimat device, which delivers a slow-moving, propellant-free mist, may result in more efficient drug delivery to the lungs compared to MDI devices. Pharmacokinetic studies suggested that the systemic exposure to the active ingredients delivered via the Respimat was generally proportional to the delivered dose.

Note on Long-Term Data: Initial long-term safety data for the Respimat device in COPD patients was a subject of regulatory review, and patients should rely on the most current prescribing information regarding its use and safety profile.

Key Studies & References

1. The role of the Respimat Soft Mist Inhaler in the treatment of COPD.

Common questions about Combivent Respimat (FAQ)

---

Q: Is Combivent Respimat considered a steroid medication?

A: Official product information states that Combivent Respimat is a combination of two types of bronchodilators: an anticholinergic agent (ipratropium bromide) and a beta2-adrenergic agonist (albuterol sulfate).

It does not contain any steroid (corticosteroid) component.

---

Q: What is the full list of active ingredients?

A: The two primary active medicinal ingredients listed in the product's official labeling are ipratropium bromide and albuterol sulfate.

Regulatory documents also indicate the presence of inactive ingredients, which typically include purified water and edetate disodium.

---

Q: How quickly can a person expect Combivent Respimat to start working?

A: Clinical studies indicate that the median time for the onset of bronchodilation (the start of the airway opening effect) is typically around 13 to 15 minutes after a dose.

This time represents the median onset observed in clinical studies.

---

Q: Is Combivent Respimat a long-term or short-term treatment?

A: Official regulatory documents indicate that Combivent Respimat is intended for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).

This classification means it is a daily medicine intended for regular, long-term scheduled use, rather than use for immediate symptom relief.

---

Q: How long do the effects of one inhalation generally last?

A: The therapeutic effects of one inhalation are generally considered to last for approximately 4 to 6 hours.

This duration is consistent with the characteristics of the recommended dosing schedule.

---

Q: Does Combivent Respimat have to be shaken before use?

A: According to the official patient instructions for the Respimat device, the inhaler does not need to be shaken before use.

Patients are instructed to follow the specific three-step procedure (Turn, Open, Press) for preparing and delivering the dose.

---

Q: Do you need to rinse your mouth after using the Respimat inhaler?

A: Official patient instructions for Combivent Respimat do not require patients to rinse their mouth after using the inhaler.

Weekly cleaning of the mouthpiece is recommended in the official patient instructions.

---

Q: Is Combivent Respimat suitable for use during pregnancy?

A: Regulatory information indicates that use during pregnancy is advised only if the potential benefit justifies the potential risk to the fetus.

The official labeling notes that the effects on labor and delivery should also be considered.

---

Q: What is known about using Combivent Respimat while breastfeeding?

A: The official product label states that there is limited available data on whether the components of this combination drug are present in human milk.

Any decision regarding the use of the medication while breastfeeding must balance the mother’s clinical need against any potential risk to the nursing infant.

---

Q: Is this drug contraindicated for people with peanut or soy allergies?

A: The Respimat device is not known to contain soy lecithin and is not contraindicated (advised against) for patients with a known soy or peanut allergy.

This is a distinction from the older Combivent Inhalation Aerosol product.

---

Q: Are there any known food or alcohol interactions with this medication?

A: The official regulatory labeling does not document specific, clinically significant interactions with common foods or alcohol.

The product label suggests a need for caution regarding the use of excessive dietary stimulants like caffeine, due to the potential for increased risk of certain adverse effects.

---

Q: Why does the Respimat inhaler have a locking mechanism?

A: The locking mechanism is a built-in safety feature of the device designed to prevent the delivery of insufficient medication.

The inhaler locks itself when the dose counter reaches zero or after the mandated three months of use, signaling that the unit is empty and should be discarded.

---

Q: Is there a generic version of Combivent Respimat available?

A: No, a generic version of the Combivent Respimat inhaler device is not currently approved by the FDA or similar agencies.

However, the individual active ingredients (ipratropium and albuterol) are available separately as generic inhalation solutions.

---

Q: Why was the older Combivent Inhalation Aerosol phased out?

A: The older Combivent Inhalation Aerosol (MDI) was phased out because it used chlorofluorocarbons (CFCs) as a propellant.

This change was made to comply with the international Montreal Protocol, which mandates the removal of ozone-depleting substances.

---

Q: What is the difference between the old Combivent and Combivent Respimat?

A: The key difference is the delivery system: Combivent Respimat uses a propellant-free soft mist and a different dosing regimen (one puff, four times a day).

Clinical trial data indicated the Respimat was clinically comparable to the older MDI in terms of lung function response.

How to Store and Dispose of Combivent Respimat?

Storing Combivent Respimat correctly is essential for maintaining its stability, as defined by official regulatory requirements.

Storage Condition	Official Regulatory Requirement
Temperature	Store at room temperature (e.g., 25 C), with excursions permitted between 15 C and 30 C.
Protection	Do not freeze. Keep the inhaler away from heat and direct light.
Child Safety	The product must be kept out of the sight and reach of children.

---

Stability and Disposal Rules

• Shelf-Life: The inhaler must be discarded three months after the cartridge is first inserted for use, or when the dose counter reaches zero, whichever comes first.
• Disposal: Unused or expired medication must be disposed of according to local regulations or returned via an approved drug take-back program. Disposal instructions require that the product not be flushed down a toilet or thrown into the household trash, to prevent environmental contamination.